About the Company
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
106
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CNST News
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Constellation Pharmaceuticals, Inc., a MorphoSys company, is the MANIFEST-2 trial sponsor. Tafasitamab is a humanized Fc-modified CD19 targeting immunotherapy. In 2010, MorphoSys licensed exclusive ...
Constellation Brands: A Hold Amid Downturns In The Wine And Spirits Category
Constellation Brands reported strong performance in its beer segment, offset by headwinds in Wine & Spirits. Read why I rate STZ stock a Hold for now.
S&P 500 Hits New Highs: Top 5 Performing Stocks Year-to-Date
So, you’re on the hunt for a remote job. You’ve polished your resume, updated your LinkedIn profile, and perfected your ...
Rocket Lab launches a commercial radar-imaging satellite in dramatic night liftoff (video)
Rocket Lab will launch a commercial radar-imaging satellite on Tuesday morning (March 12), and you can watch the action live.
Planful Named to Constellation Research ShortList™ for Cloud-Based Planning and Performance Management Platforms for 12th Consecutive Year
Planful Inc., the pioneer of financial performance management cloud software, today announced that the company was named to ...
Street Calls of the Week: Upgrades for MediaAlpha and Constellation Energy
How did the stock react? MediaAlpha traded up on the premarket headlines from $20.02 to $20.79, a gain of 4%. MediaAlpha ...
Canada’s IPO Drought Reaches a Full Year With No End in Sight
Canada’s biggest market for initial public offerings is marking a grim milestone of a full year without a new corporate ...
Rocket Lab launches Synspective radar imaging satellite
Rocket Lab launched a radar imaging satellite for Japanese company Synspective March 12, the latest in a series of launches ...
Rocket Lab Successfully Launches 45th Electron Mission, 4th for Longtime Partner Synspective
Rocket Lab USA, Inc. (Nasdaq: RKLB) ("Rocket Lab" or "the Company"), a global leader in launch services and space systems, ...
Idorsia and Viatris successfully close the transaction for the global research and development collaboration
Idorsia Ltd (SIX: IDIA) today announced that it has successfully closed the transaction with Viatris Inc. (NASDAQ: VTRS), a ...
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Annual ReportMorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update 13.03.2024 / 21:01 CET/CESTThe issuer is solely responsible for the content of this ...
Loading the latest forecasts...